Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement... Show more
a provider of original medical equipment for medical personnel
Industry PharmaceuticalsOther
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FETH | 26.89 | 0.32 | +1.20% |
| Fidelity Ethereum Fund ETF (FETH) | |||
| JHAI | 35.92 | 0.35 | +1.00% |
| Janus Henderson Global Artificial Intelligence ETF (JHAI) | |||
| ZOCT | 28.19 | 0.07 | +0.25% |
| Innovator 1 Yr October (ZOCT) | |||
| IQSU | 62.74 | 0.12 | +0.19% |
| NYLIM Candriam U.S. Large Cap Equity ETF (IQSU) | |||
| CHAI | 0.28 | N/A | +0.04% |
| Core AI Holdings Inc | |||
A.I.dvisor tells us that DXR and IART have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DXR and IART's prices will move in lockstep.
| Ticker / NAME | Correlation To DXR | 1D Price Change % | ||
|---|---|---|---|---|
| DXR | 100% | -3.38% | ||
| IART - DXR | 33% Poorly correlated | -1.17% | ||
| BWAY - DXR | 27% Poorly correlated | -4.55% | ||
| AVTR - DXR | 23% Poorly correlated | -0.13% | ||
| COO - DXR | 20% Poorly correlated | +1.56% | ||
| SHC - DXR | 20% Poorly correlated | -2.00% | ||
More | ||||
| Ticker / NAME | Correlation To DXR | 1D Price Change % |
|---|---|---|
| DXR | 100% | -3.38% |
| Pharmaceuticals: Other industry (50 stocks) | 5% Poorly correlated | -0.52% |
| Pharmaceuticals industry (154 stocks) | -5% Poorly correlated | -0.74% |
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where DXR declined for three days, in 142 of 195 cases, the price declined further within the following month. The odds of a continued downward trend are 73%.
The 10-day RSI Indicator for DXR moved out of overbought territory on September 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 15 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 66 cases where DXR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DXR as a result. In 91 of 128 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
The Moving Average Convergence Divergence Histogram (MACD) for DXR turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 63 similar instances when the indicator turned negative. In 40 of the 63 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.
DXR broke above its upper Bollinger Band on September 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
DXR moved above its 50-day moving average on September 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for DXR crossed bullishly above the 50-day moving average on September 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
Following a +8.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXR advanced for three days, in 139 of 211 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 171 of 228 cases where DXR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. DXR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.278) is normal, around the industry mean (5.011). P/E Ratio (6.716) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (3.480) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (8.389) is also within normal values, averaging (56.074).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.